Abstracts

2020


2018


2016


• Cheung WY, Mittmann N, Leigil NB, Cheung MC, Bradbury PA, Ng RCH, Chen BE, Ding K, Pater JL, Tu D, Hay AE. The economic impact of the transition from branded to generic oncology drugs. J Clin Oncol 34[Suppl; abstr 6520]. 2016.


• de Boer SM, Powell ME, Mileshkin LR, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles AW, Baron M-H, Kitchener HC, Nijman H, Kruijtvagen RFPM, Jurgenliemk-Shultz IM, Nout RA, Smit VTHBM, Putter H, Creutzberg CL. Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-


Strasser-Weippl K, Sudan G, Ramjeesingh R, Shepherd LE, O'Shaughnessy J, Chen BE, Parulekar WR, Liedke PER, Goss PE. Outcomes of invasive ductal (ID) or invasive lobular (IL) early stage breast cancer in women treated with anastrozole or exemestane


• Arts KE, Kato D, Dancey J. Establishment of a baseline to measure academic clinical trial activity in Canada. J Clin Oncol 33[suppl; abstr e17547].


• Parimi S, Karachiwala H, Lin Y, Monzon JG, Tam VC, Chen EX, Dancey J, Tang PA. Critical assessment of phase 0 (Ph0) and window of opportunity (WOO) trials: Definitions and reporting. J Clin Oncol 33[Suppl; abstr e17710].


• Pennngton MG. Full report of the TROG 03.01, NCIC CTG ES2 multinational phase III study in advanced esophageal cancer comparing palliation of dysphagia and quality of life in patients treated with radiotherapy or chemoradiotherapy. J Clin Oncol 33[(Suppl 3; abstr 6)]. 2015.


metformin (Met) to placebo (Pl). J Clin Oncol 32:5s[suppl; abstr 542]. 2014.


2013


- Moy B, Tu D, Richardson H, Maunsell E, Goss PE. NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. J Clin Oncol 31[suppl; abstr 6557], 2013.


- Renouf DJ, Parulekar W, Grigorieva J, Tu D, Moore MJ. Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. J Clin Oncol 31[suppl; abstr 4061], 2013.


2012


• Eisenhauer EA. Antiangiogenics in ovarian cancer: where are we now? Ann Oncol 23[suppl 9, abstr 54IN], ix40-ix41, 2012.


- Liedke PER, Chavarri-Guerra Y, Shepherd LE, Tu D, Pritchard KI, Goss PE. Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17. J Clin Oncol 30[ suppl, abstr 524], 2012.


- Pitz MW, MacNeil MV, Macdonald DR, Kakumanu AS, Thiessen B, Tsao MS, Kamel-


- Steele R, Quirke P, Grieve R, Monson J, Couture J, de Metz C, Pugh C, Nichols L, Thompson LC, Sebag-Montefiore D, on behalf of all investigators MCTUL. Long Term Outcome After Anastomotic Leak and the Impact of Short Course Pre-Operative Radiotherapy - Data from the MRC CRO7 NCIC CO16 trial. 6th European Multidisciplinary Colorectal Cancer Congress, 2012.


- Waldron JN, Parulekar W, O’Sullivan B, Chen BE, Montenegro A, Nabi A, Winquist E,


2011


• Cuffe S, Graziano S, Bourrejdem A, Pignon J-P, Ezzaldfani M, Seymour L, Strevel E, Burkes R, Capelletti M, Janne PA, Tsao MN, Shepherd FA. A pooled exploratory analysis of the impact of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy (ACT) in node negative (N0) non-small cell lung cancer (NSCLC). J Thoracic Oncol 6[6 suppl 2, abstr O42.01], S462, 2011.

Abstracts
Published on Canadian Cancer Trials Group (https://www.ctg.queensu.ca)

suppl 2, abstr MO19.03], S641, 2011.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

Conference, 2011.


• Li X, Chen J, Wu Y, Tu D. Variable selections in the Cox proportional hazards model based on extended bayesian information criteria. 32nd Annual Conference of the International Society for Clinical Biostatistics, 2011.


• Meyer RM, Gospodarowicz M, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE. Final Analysis of a Randomized Comparison of ABVD Chemotherapy with a Strategy


2010


- Alberts SR, Sargent DJ, Smyrk TC, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Thibodeau SN, Nair S. Adjuvant mFOLFOX6 with or without cetuximab in KRAS wild-type patients with resected stage III colon cancer: Results from NCCTG Intergroup Phase III Trial N0147. J Clin Oncol 28[18s, abstr CRA3507], 2010.


Eisenhauer E. In search of intermediate endpoints. EORTC-NCI-AACR Symposium [abstr 29], 2010.


Radich JP, Kopecky KJ, Kamel-Reid S, Stock W, Paietta E, Wadleigh M, Larson RA, Emanuel PD, Tallman MS, Lipton J, Couban S, Deininger MW, Appelbaum FR, Druker BJ. A Randomized Phase II Trial of Dasatinib 100 Mg Vs Imatinib 400 Mg In Newly


2010.


2009


- Craddock KJ, Buys TPH, Zhu CQ, Strumpf D, Pintillie M, Ding K, Seymour L, Jurisica I, Shepherd FA, Lam WL, Tsao M-S. High resolution genomic analysis of NSCLC reveals regions of DNA copy number gain that may be predictive of benefit from adjuvant chemotherapy. J Thoracic Oncol 4[9 suppl 1, abstr PD12.2.6], S580. 2009.


with lapatinib or trastuzumab as first-line therapy for women with HER2/neu positive metastatic breast cancer (NCIC CTG MA.31/EGF108919). ASCO Breast Cancer Symposium, 2009.


- Kouroukis CT, Hafid T, Wong J, Kovacs MJ, Barr R, Findlay B, Shepherd L, Djurfeldt M, Ding K, Zhu L, Shustik C, Meyer R. Comorbidity, age and performance status are important predictors of outcome in older multiple myeloma patients treated with melphalan and corticosteroids; subgroup analysis from the National Cancer Institute of
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


- Palmer M, Broxterman J, Shepherd L, Parulekar W. Tracking patients on an intergroup oncology study. It’s a snap! Clinical Trials 6, 536, 2009.


Bradbury PA, Tu D, Seymour L, Ng R, Zhu L, Isogai PK, Mittmann N, Evans WK, Shepherd FA, Leighl NB, on behalf of the NCIC CTG Working Group on Economic Analysis. Impact of clinical and molecular predictors of benefit from erlotinib in advanced


- Lerner SP, Stein JP, Stadler WM, Groshen S, Tuazon E, Skinner DG, Raghavan D, Esrig D, Steinberg G, Hall C, Cote R. Results of the p53 targeted therapy trial for
patients with organ confined node negative bladder cancer treated with radical cystectomy. Society of Urologic Oncology, 2008.


- Pollak MN, Chapman JW, Pritchard KI, Krook JE, Dhaliwal HS, Vandenberg TA, Norris BD, Whelan TJ, Wilson CF, Shepherd LE. NCIC-CTG MA14 trial: Tamoxifen (tam) vs. tam + octreotide (oct)for adjuvant treatment of stage I or II postmenopausal breast


- Schell AJ, Young I, Hansen C, Chi KN, Taylor S. BRAF mutation status and growth factor receptor expression do not predict baseline factors or outcome in hormone refractory prostate carcinoma. United States and Canadian Academy of Pathology, 2008.


- Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, Johnson N, Verheijen


2007


- Au H-J, Brundage M, Ringash J, Bezkja A, Palmer M, Richardson H, Lee CW, Maunsell


trial in prostate cancer of radiotherapy timing and hormone therapy duration after radical prostatectomy (MRC PR10, NCIC PR13, ISRCTN40814031). NCRI United Kingdom, 2007.


• Tu D. Identification of patients who will benefit from a treatment based on their genetic profiles: Some examples and statistical issues. Workshop on Statistical Analysis of High-Throughput Genetic Data, 2007.


2006


• Chen CI, Kouroukis T, White D, Voralia M, Stadtmauer E, Wright J, Powers J, Eisenhauer E. Bortezomib is active in Waldenström's Macroglobulinemia (WM) - Results
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andruslis I, Pritchard KL. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). Breast Cancer Research and Treatment 100[Suppl 1], S18, 2006.

• O'Malley FP, Chia S, Tu D, Shepherd LE, Levine MN, Huntsman DG, Bramwell VH, Andruslis IL, Pritchard KL. Prognostic and predictive value of topoisomerase II alpha in a


maintaining hemoglobin = 120 G/L with erythropoietin during chemoradiation for cervical cancer. Int J Gynecol Cancer 16[3], 603-604, 2006.


2005


- Goss PE, Ingle J, Tu D, Shepherd L, Pater J. NCIC CTG MA17: Disease free survival


• Li D. Determinants of sample size and power in equivalence trials that compare binomial outcomes. Clinical Trials 2[Suppl 1], S59, 2005.

• Li D. Can more frequent regular group sequential tests help to make an earlier conclusion in clinical trials? A retrospective evaluation. Clinical Trials 2[Suppl 1], 2005.


• Maunsell E, Au H, Palmer M, Tu D, Whelan TJ, Goss PE, Davis A. Health-related quality of life in breast cancer survivors after 5 years of adjuvant tamoxifen. Quality of Life Research 14[9], 2092, 2005.

• Messerschmidt T, Koski B. Integrating SOPs into a comprehensive website document management system. Clinical Trials 2[Suppl 1], S50, 2005.


• Tu D. Nonparametric estimate and confidence intervals for the hazard ratio based on censored data. Clinical Trials 2[Suppl 1], S36, 2005.

2004

• Chi K, Eisenhauer E, Fazli L, Jones EC, Powers J, Hurtado-Coll A, Goldenberg L, Gleave ME. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2’methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer


- Ding K. Point estimate following group sequential tests. ENAR Int Biometric Soc, 2004.


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


• Ehrenberger H, Bacon M, Burkes K, Lillington L, Ward K, Zimmerman J. The
development of a virtual work group of the ONS Clinical Trials Nurses Special Interest Group: Keys to productivity. Oncology Nursing Society, 2003.


2002

- Bezjak A, Perrone F, Gallo C, Hirsh V, Seymour L, Plantedosi F, Shepherd F, Robbiati


Madarnas Y, Fine S, Sawka C, Shepherd L, Tannock I, Tu D, Levine M. Body size,
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


2001


• Crump M, Tu D, Shepherd L, Levine E, Bramwell V, Pritchard K. Risk of acute leukemia


2000


Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


21(2S), 114s, 2000.


1999


1998


Pater J, Bezjak A, Osoba D, Zee B, Palmer M. Quality of life as an endpoint in NCIC


1997

- Dent S, Klaassen D, Pater J, Zee B, Whitehead M. Update of second primary malignancies and treatment results in women with early stage ovarian cancer.


1996


- Zee B. Phase II design for cancer clinical trials using multivariate endpoints. Biometric Society ENAR, 1996.


1995


- Latreille J, Johnston D, Laberge F, Stewart D, Rusthoven J, Nishimura L, Pater J, Zee B.
Use of granisetron and dexamethasone on day 2-7 following high dose cisplatin. Supportive Care in Cancer 3(5), 339, 1995.


- Lofters C, Zee B. Adding 5 HT3 antagonists to dexamethasone after 24 hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Eur.J.Can. 31A(suppl.5), 255, 1995.


- Lofters W, Zee B. Adding 5HT3 antagonists to dexamethasone after twenty four hours has a minimal effect in preventing delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. Supportive Care in Cancer 3(5), 339, 1995.


- Pater J, Zee B, Lofters W, Osoba D, Warr D, Palmer M, Chin C, Dempsey E. Effective


1994


- Eisenhauer E, Bacon M, Atri M, Lemort M, Nolan R, Petroons P, Sauerbrei E, Florczyk


- Zee B, James K, Johnston D. Design and analysis of late randomization trials:

1993

Tumour Research and Therapy, 1993.

- Paul N. The success of clinical trials depends on good communication. Joint meeting of EORTC SGDM and BODMA, 1993.


- Pater J, Niezgoda H, Zee B. Validation of the EORTC-QLC -- a comparison with four other instruments in a heterogenous group of cancer patients. Ann.Oncol. 3(Suppl.5), 175, 1992.
- Zee B. One-sided test for clinical trials with group sequential design that allow early
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1991


304, 1990.


1989

Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)

- Palmer M, Pater J. Comparison of errors in body surface area and initial doses in five clinical trials (C0.2, C0.3, HD.4, MA.4, OV.8). Controlled Clin.Trials 10(3), 351, 1989.

1988


1987

1986

- Wallenstein S, Patel HI, Willan A. Use of baseline values in the two period two treatment crossover design. Biometric Society ENAR, 1986.

1985
Abstracts
Published on Canadian Cancer Trials Group
(https://www.ctg.queensu.ca)


1984


1983


1981